Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
June 3, 2026

Roche’s giredestrant secures FDA priority review for breast cancer

The US Food and Drug Administration (FDA) has accepted priority review of the new drug application (NDA) for Roche’s investigational oral selective oestrogen receptor degrader (SERD), giredestrant, for breast cancer.

Continue
The filing acceptance is based on Phase III data from the lidERA Breast Cancer study. Credit: Arif biswas / Shutterstock.com.
June 3, 2026

AbbVie receives EC approval for Aquipta to treat migraine

The ECLIPSE study showed Aquipta was more effective than placebo in achieving pain freedom at two hours after the first migraine attack treatment. Credit: Studio Romantic / Shutterstock.com.
June 2, 2026

BMS secures FDA acceptance for Camzyos sNDA

Camzyos is currently approved for symptomatic NYHA Class II-III oHCM in adults to improve functional capacity and symptoms. Credit: NMK-Studio / Shutterstock.com.

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn
  2. Lilly and Hanmi sign $1.26bn licensing deal for sonefpeglutide
  3. FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy
  4. Pfizer and Innovent Biologics sign $10.5bn cancer drug development deal
  5. FDA grants priority review for Sanofi’s venglustat NDA

PRESS RELEASES

SCHOTT Pharma and SHL Medical Enhance Home-Based Large-Volume Injections for Patients
SCHOTT Pharma and SHL Medical Enhance Home-Based Large-Volume Injections for Patients
SCHOTT Pharma Launches Ready-to-Use Polymer Cartridge
SCHOTT Pharma Launches Ready-to-Use Polymer Cartridge
Accelerating Self-Administration and Homecare: SCHOTT Pharma Launches Large-Volume Prefillable Glass Syringe
Accelerating Self-Administration and Homecare: SCHOTT Pharma Launches Large-Volume Prefillable Glass Syringe
Pharmaceutical Business Review
Christian Mias to Succeed Andreas Reisse as CEO of SCHOTT Pharma
Pharmaceutical Business Review
LTS completes acquisition of Renaissance Lakewood, expanding global CDMO capabilities

Suppliers

Whitepapers

Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography